NewAmsterdam Pharma Corporation
@newamsterdampharma.bsky.social
NewAmsterdam Pharma Corporation is a late-stage clinical biopharma company developing therapies for cardiometabolic diseases. Intended for US audiences only.
https://newamsterdampharma.com
https://newamsterdampharma.com
A recent study found only ~40% of ASCVD patients achieved guideline-recommended LDL-C targets, highlighting the need for frequent follow-up, patient counseling, and combination therapies. Learn more about the unmet need in cardiovascular disease: www.newamsterdampharma.com/unmet-need-c...
November 18, 2025 at 3:14 PM
A recent study found only ~40% of ASCVD patients achieved guideline-recommended LDL-C targets, highlighting the need for frequent follow-up, patient counseling, and combination therapies. Learn more about the unmet need in cardiovascular disease: www.newamsterdampharma.com/unmet-need-c...
About 1 in 9 adults worldwide are living with diabetes, and the diagnosis doubles the risk for heart disease. People with type 2 diabetes have a similar risk of CVD as those who already have it.
This #WorldDiabetesDay, learn more about our research: www.newamsterdampharma.com/lipid-relate...
This #WorldDiabetesDay, learn more about our research: www.newamsterdampharma.com/lipid-relate...
November 14, 2025 at 4:06 PM
About 1 in 9 adults worldwide are living with diabetes, and the diagnosis doubles the risk for heart disease. People with type 2 diabetes have a similar risk of CVD as those who already have it.
This #WorldDiabetesDay, learn more about our research: www.newamsterdampharma.com/lipid-relate...
This #WorldDiabetesDay, learn more about our research: www.newamsterdampharma.com/lipid-relate...
Lowering LDL-C is essential for cardiovascular risk reduction, but it’s not enough on its own. Our CEO Dr. Michael Davidson details why the future of hyperlipidemia management needs to go beyond LDL-C. bit.ly/3LAQSCA
November 13, 2025 at 3:03 PM
Lowering LDL-C is essential for cardiovascular risk reduction, but it’s not enough on its own. Our CEO Dr. Michael Davidson details why the future of hyperlipidemia management needs to go beyond LDL-C. bit.ly/3LAQSCA
Happening now at #AHA25: José Inia leads a digital poster presentation on a preclinical analysis evaluating a combination approach to targeting atherosclerotic plaque lesions. Review the abstract to learn more about our investigational CETP inhibitor: eppro02.ativ.me//web/index.p...
November 10, 2025 at 5:06 PM
Happening now at #AHA25: José Inia leads a digital poster presentation on a preclinical analysis evaluating a combination approach to targeting atherosclerotic plaque lesions. Review the abstract to learn more about our investigational CETP inhibitor: eppro02.ativ.me//web/index.p...
LDL-C isn’t the whole picture. Other factors like LDL particles, ApoB, Lp(a), non-HDL-C, and low HDL-C can contribute to residual ASCVD risk.
Learn about each of these factors: www.expectmoreforldl.com/ldl-c-and-be...
Learn about each of these factors: www.expectmoreforldl.com/ldl-c-and-be...
November 9, 2025 at 8:15 PM
LDL-C isn’t the whole picture. Other factors like LDL particles, ApoB, Lp(a), non-HDL-C, and low HDL-C can contribute to residual ASCVD risk.
Learn about each of these factors: www.expectmoreforldl.com/ldl-c-and-be...
Learn about each of these factors: www.expectmoreforldl.com/ldl-c-and-be...
ASCVD risk reduction begins with lowering LDL-C, but residual cardiovascular risk remains and contributes to 400,000 deaths in the US each year. To change that trajectory, we’re challenging ourselves to expect more from lipid-lowering therapies. www.expectmoreforldl.com?utm_source=s...
November 8, 2025 at 1:29 PM
ASCVD risk reduction begins with lowering LDL-C, but residual cardiovascular risk remains and contributes to 400,000 deaths in the US each year. To change that trajectory, we’re challenging ourselves to expect more from lipid-lowering therapies. www.expectmoreforldl.com?utm_source=s...
New this weekend at #AHA25: Don’t miss our CSO Dr. John Kastelein’s oral presentation on an analysis of pooled LDL particle data from our Phase 3 program evaluating our investigational CETP inhibitor.
Make sure this session is part of your conference plan: eppro02.ativ.me/appinfo.php?...
Make sure this session is part of your conference plan: eppro02.ativ.me/appinfo.php?...
November 7, 2025 at 4:10 PM
New this weekend at #AHA25: Don’t miss our CSO Dr. John Kastelein’s oral presentation on an analysis of pooled LDL particle data from our Phase 3 program evaluating our investigational CETP inhibitor.
Make sure this session is part of your conference plan: eppro02.ativ.me/appinfo.php?...
Make sure this session is part of your conference plan: eppro02.ativ.me/appinfo.php?...
We closed the third quarter with continued momentum—advancing our clinical programs, sharing new scientific insights, and preparing for what’s ahead.
Read our latest corporate update and Q3 2025 financial results: ir.newamsterdampharma.com/news-release...
Read our latest corporate update and Q3 2025 financial results: ir.newamsterdampharma.com/news-release...
November 5, 2025 at 4:58 PM
We closed the third quarter with continued momentum—advancing our clinical programs, sharing new scientific insights, and preparing for what’s ahead.
Read our latest corporate update and Q3 2025 financial results: ir.newamsterdampharma.com/news-release...
Read our latest corporate update and Q3 2025 financial results: ir.newamsterdampharma.com/news-release...
Even when taking statins, many ASCVD patients face residual cardiovascular risk.
October 28, 2025 at 4:29 PM
Even when taking statins, many ASCVD patients face residual cardiovascular risk.
LDL-C is only part of the story. Research published in Frontiers suggests that LDL particle number (LDL-P) is a more accurate predictor of cardiovascular risk than LDL-C.
Read the article: www.frontiersin.org/journals/phy...
Read the article: www.frontiersin.org/journals/phy...
October 27, 2025 at 2:20 PM
LDL-C is only part of the story. Research published in Frontiers suggests that LDL particle number (LDL-P) is a more accurate predictor of cardiovascular risk than LDL-C.
Read the article: www.frontiersin.org/journals/phy...
Read the article: www.frontiersin.org/journals/phy...
We’re excited to see our Alzheimer’s disease biomarker data from a prespecified substudy in our BROADWAY clinical trial has been peer-reviewed and published in the Journal of Prevention of Alzheimer’s Disease. 🔓 Read the open access article: www.newamsterdampharma.com/wp-content/u...
October 20, 2025 at 2:07 PM
We’re excited to see our Alzheimer’s disease biomarker data from a prespecified substudy in our BROADWAY clinical trial has been peer-reviewed and published in the Journal of Prevention of Alzheimer’s Disease. 🔓 Read the open access article: www.newamsterdampharma.com/wp-content/u...
Combination lipid-lowering therapy could prevent 330K deaths globally every year, according to a recent meta-analysis. The findings, drawn from data on over 108,000 patients, make a case to rethink the standard treatment approach.
Read more: www.mayoclinicproceedings.org/pb-assets/He...
Read more: www.mayoclinicproceedings.org/pb-assets/He...
October 15, 2025 at 3:34 PM
Combination lipid-lowering therapy could prevent 330K deaths globally every year, according to a recent meta-analysis. The findings, drawn from data on over 108,000 patients, make a case to rethink the standard treatment approach.
Read more: www.mayoclinicproceedings.org/pb-assets/He...
Read more: www.mayoclinicproceedings.org/pb-assets/He...
Despite gradual improvements from 2014 to 2023, too many people with ASCVD are falling short of guideline-recommended lipid levels or not receiving treatment. We’re working to close this gap by advancing therapies with the potential to help more people reach their goals. bit.ly/476bTgz
October 2, 2025 at 6:43 PM
Despite gradual improvements from 2014 to 2023, too many people with ASCVD are falling short of guideline-recommended lipid levels or not receiving treatment. We’re working to close this gap by advancing therapies with the potential to help more people reach their goals. bit.ly/476bTgz
Despite being on lipid-lowering therapies, many patients still have LDL-C levels above recommended targets. This LDL-C Awareness Day, take a moment for your health—talk to your doctor and see if it's time for a cholesterol check.
September 30, 2025 at 3:17 PM
Despite being on lipid-lowering therapies, many patients still have LDL-C levels above recommended targets. This LDL-C Awareness Day, take a moment for your health—talk to your doctor and see if it's time for a cholesterol check.
This World Heart Day, we’re joining the global call to reduce the burden of cardiovascular disease, the world’s leading cause of death. Our mission: advance research in pursuit of a future where heart disease is no longer the #1 killer.
Learn more at bit.ly/3VCUu8V
Learn more at bit.ly/3VCUu8V
September 29, 2025 at 5:41 PM
This World Heart Day, we’re joining the global call to reduce the burden of cardiovascular disease, the world’s leading cause of death. Our mission: advance research in pursuit of a future where heart disease is no longer the #1 killer.
Learn more at bit.ly/3VCUu8V
Learn more at bit.ly/3VCUu8V
A new analysis in @jme-journal.bsky.social identifies a costly gap in heart health. A majority of Americans with hypercholesterolemia are on statins, but most don't hit their LDL-C targets. Getting to goal was associated with a 50% reduction in cardiovascular events. bit.ly/48xvWWf
September 25, 2025 at 1:13 PM
A new analysis in @jme-journal.bsky.social identifies a costly gap in heart health. A majority of Americans with hypercholesterolemia are on statins, but most don't hit their LDL-C targets. Getting to goal was associated with a 50% reduction in cardiovascular events. bit.ly/48xvWWf
>7M Americans live with Alzheimer’s, and that number could reach 13M by 2050. Cholesterol plays a critical role in brain health, and research suggests there could be a link between lipid metabolism in the brain and Alzheimer’s. Take a closer look at the science: bit.ly/3KhaOty
September 24, 2025 at 2:28 PM
>7M Americans live with Alzheimer’s, and that number could reach 13M by 2050. Cholesterol plays a critical role in brain health, and research suggests there could be a link between lipid metabolism in the brain and Alzheimer’s. Take a closer look at the science: bit.ly/3KhaOty
Nimble, agile, and locked in with our patient focus. Our Chief Commercial Officer BJ Jones shares some of what makes our culture unique, from having a still-practicing clinician as CEO, to the clarity of our shared mission.
Learn more about us: www.newamsterdampharma.com/aboutus?utm_...
Learn more about us: www.newamsterdampharma.com/aboutus?utm_...
September 22, 2025 at 12:44 PM
Nimble, agile, and locked in with our patient focus. Our Chief Commercial Officer BJ Jones shares some of what makes our culture unique, from having a still-practicing clinician as CEO, to the clarity of our shared mission.
Learn more about us: www.newamsterdampharma.com/aboutus?utm_...
Learn more about us: www.newamsterdampharma.com/aboutus?utm_...
We’re excited to join the patients, clinicians, and researchers gathering for #FHFSummit25 with the goal of “Catalyzing Collective Action for Lp(a) & FH.” As sponsors, we look forward to being part of conversations that lead to meaningful change. familyheart.org/2025-family-...
September 17, 2025 at 11:51 AM
We’re excited to join the patients, clinicians, and researchers gathering for #FHFSummit25 with the goal of “Catalyzing Collective Action for Lp(a) & FH.” As sponsors, we look forward to being part of conversations that lead to meaningful change. familyheart.org/2025-family-...
Addressing cholesterol dysregulation in the brain may help delay the formation of amyloid plaque and tau tangle buildup that contributes to Alzheimer’s disease. Explore the science: bit.ly/42naX4D
September 8, 2025 at 2:54 PM
Addressing cholesterol dysregulation in the brain may help delay the formation of amyloid plaque and tau tangle buildup that contributes to Alzheimer’s disease. Explore the science: bit.ly/42naX4D
Watch and listen as our leaders participate in fireside chats at three upcoming investor conferences—all before the end of the week. Live webcasts will be available through our website. Mark your calendar: ir.newamsterdampharma.com/news-release...
September 2, 2025 at 12:19 PM
Watch and listen as our leaders participate in fireside chats at three upcoming investor conferences—all before the end of the week. Live webcasts will be available through our website. Mark your calendar: ir.newamsterdampharma.com/news-release...
Prof Stephen Nicholls shared major adverse cardiovascular event (MACE) outcomes based on an analysis of pooled data from our Phase 3 BROOKLYN & BROADWAY studies of our investigational drug therapy, obicetrapib. The data were also simultaneously published in @jaccjournals.bsky.social: bit.ly/4mHrXeb
September 1, 2025 at 12:22 PM
Prof Stephen Nicholls shared major adverse cardiovascular event (MACE) outcomes based on an analysis of pooled data from our Phase 3 BROOKLYN & BROADWAY studies of our investigational drug therapy, obicetrapib. The data were also simultaneously published in @jaccjournals.bsky.social: bit.ly/4mHrXeb
Tomorrow at #ESCCongress, Professor Kausik Ray will discuss data on our investigational CETP inhibitor as an add-on to background lipid-lowering therapies in a pooled analysis of our BROADWAY and BROOKLYN trials. esc365.escardio.org/esc-congress...
August 28, 2025 at 3:13 PM
Tomorrow at #ESCCongress, Professor Kausik Ray will discuss data on our investigational CETP inhibitor as an add-on to background lipid-lowering therapies in a pooled analysis of our BROADWAY and BROOKLYN trials. esc365.escardio.org/esc-congress...
We’re looking forward to #ESCCongress, where our data will be featured in multiple sessions. Presentations will cover:
❤️ MACE data from our BROADWAY and BROOKLYN studies
❤️ CETPi as an add-on LLT in the BROADWAY and BROOKLYN studies
More: ir.newamsterdampharma.com/news-release...
❤️ MACE data from our BROADWAY and BROOKLYN studies
❤️ CETPi as an add-on LLT in the BROADWAY and BROOKLYN studies
More: ir.newamsterdampharma.com/news-release...
August 25, 2025 at 12:11 PM
We’re looking forward to #ESCCongress, where our data will be featured in multiple sessions. Presentations will cover:
❤️ MACE data from our BROADWAY and BROOKLYN studies
❤️ CETPi as an add-on LLT in the BROADWAY and BROOKLYN studies
More: ir.newamsterdampharma.com/news-release...
❤️ MACE data from our BROADWAY and BROOKLYN studies
❤️ CETPi as an add-on LLT in the BROADWAY and BROOKLYN studies
More: ir.newamsterdampharma.com/news-release...
ApoE, a protein encoded by the APOE gene, helps transport and clear cholesterol. The APOE4 variant is less efficient in these tasks, increasing the risk for both cardiovascular and Alzheimer’s disease.
Learn more about APOE4, cholesterol, and the brain: bit.ly/45pvqrA
Learn more about APOE4, cholesterol, and the brain: bit.ly/45pvqrA
August 20, 2025 at 4:19 PM
ApoE, a protein encoded by the APOE gene, helps transport and clear cholesterol. The APOE4 variant is less efficient in these tasks, increasing the risk for both cardiovascular and Alzheimer’s disease.
Learn more about APOE4, cholesterol, and the brain: bit.ly/45pvqrA
Learn more about APOE4, cholesterol, and the brain: bit.ly/45pvqrA